Resolution Therapeutics to Participate in the Jefferies Global Healthcare Conference
Edinburgh and London, UK, 28 May 2024 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering engineered autologous macrophage cell therapies to transform the treatment of inflammatory organ diseases, today announced that Amir Hefni, Ph.D., Chief Executive Officer, and Simon Ramsden, Chief Financial Officer, will participate in meetings with investors at the Jefferies Global Healthcare Conference on Tuesday, June 4, 2024, in New York, NY. Investors are encouraged to contact their Jefferies representative to schedule a meeting.